tbuckley/cabot-search huggingface dataset:
Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis
Authors: Douglas A. Corley, Christopher D. Jensen, Virginia P. Quinn, Chyke A. Doubeni, Ann G. Zauber, Jeffrey K. Lee, Joanne E. Schottinger, Amy R. Marks, Wei K. Zhao, Nirupa R. Ghai, Alexander T. Lee, Richard Contreras, Charles P. Quesenberry, Bruce H. Fireman, Theodore R. Levin
Journal: JAMA (2017)

The fecal immunochemical test (FIT) is commonly used for colorectal cancer screening and positive test results require follow-up colonoscopy. However, follow-up intervals vary, which may result in neoplastic progression.To evaluate time to colonoscopy after a positive FIT result and its association with risk of colorectal cancer and advanced-stage disease at diagnosis.Retrospective cohort study (January 1, 2010-December 31, 2014) within Kaiser Permanente Northern and Southern California. Participants were 70 124 patients aged 50 through 70 years eligible for colorectal cancer screening with a positive FIT result who had a follow-up colonoscopy.Time (days) to colonoscopy after a positive FIT result.Risk of any colorectal cancer and advanced-stage disease (defined as stage III and IV cancer). Odds ratios (ORs) and 95% CIs were adjusted for patient demographics and baseline risk factors.Of the 70 124 patients with positive FIT results (median age, 61 years [IQR, 55-67 years]; men, 52.7%), there were 2191 cases of any colorectal cancer and 601 cases of advanced-stage disease diagnosed. Compared with colonoscopy follow-up within 8 to 30 days (n = 27 176), there were no significant differences between follow-up at 2 months (n = 24 644), 3 months (n = 8666), 4 to 6 months (n = 5251), or 7 to 9 months (n = 1335) for risk of any colorectal cancer (cases per 1000 patients: 8-30 days, 30; 2 months, 28; 3 months, 31; 4-6 months, 31; and 7-9 months, 43) or advanced-stage disease (cases per 1000 patients: 8-30 days, 8; 2 months, 7; 3 months, 7; 4-6 months, 9; and 7-9 months, 13). Risks were significantly higher for examinations at 10 to 12 months (n = 748) for any colorectal cancer (OR, 1.48 [95% CI, 1.05-2.08]; 49 cases per 1000 patients) and advanced-stage disease (OR, 1.97 [95% CI, 1.14-3.42]; 19 cases per 1000 patients) and more than 12 months (n = 747) for any colorectal cancer (OR, 2.25 [95% CI, 1.89-2.68]; 76 cases per 1000 patients) and advanced-stage disease (OR, 3.22 [95% CI, 2.44-4.25]; 31 cases per 1000 patients).Among patients with a positive fecal immunochemical test result, compared with follow-up colonoscopy at 8 to 30 days, follow-up after 10 months was associated with a higher risk of colorectal cancer and more advanced-stage disease at the time of diagnosis. Further research is needed to assess whether this relationship is causal.
Clinical Implementation of a Testing Algorithm for the Diagnosis of Ph-like B-Cell Acute Lymphoblastic Leukemia
Authors: Xinyan Lu, Alexandra Reynolds, Sergej Konopleva, Sa Wang, Kathryn G. Roberts, Charles Mullighan, Guilin Tang, Zhenya Tang, Patrick Zweidler-McKay, Jeffrey L. Jorgensen, Keyur P. Patel, L. Jeffrey Medeiros, Pei Lin, Marina Konopleva, Nitin Jain
Journal: Blood (2016)
Acupuncture May Be Effective for Long-term Migraine Prophylaxis
Authors: Anita Slomski
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Advanced Training Workshop: Psychosomatic Assessment
Authors: Franz Caspar, P. Bech, Graeme J. Taylor, Felicity L. Bishop, Fiona Barlow, Jan Walker, Clare McDermott, George T. Lewith, Alexander Heinzel, Ralf Schäfer, Hans-Wilhelm Müller, Andre Schieffer, Ariane Ingenhag, Simon B. Eickhoff, Georg Northoff, Matthias Franz, Hubertus Hautzel, A. Lok, T.L.S. Visscher, M.W.J. Koeter, J. Assies, C.L.H. Bockting, W.M.M. Verschuren, A. Gill, A.H. Schene, Harald Baumeister, Gordon Parker, K.M.L. Huijbregts, H.W.J. van Marwijk, F.J. de Jong, B. Schreuders, A.T.F. Beekman, C.M. van der Feltz-Cornelis, William Y. Shi, Andrew G. Stewart, David L. Hare, Paola Rocca, Mario Aimetti, Michela Giugiario, Enrico Pigella, Federica Romano, Barbara Crivelli, Giuseppe Rocca, Filippo Bogetto, Jaap Lancee, Victor I. Spoormaker, Jan van den Bout, Marleen De Bolle, Jeffrey G. Johnson, Filip De Fruyt
Journal: Psychotherapy and Psychosomatics (2010)

Sonino (Italy), Tom Wise (USA) and Jesse Wright (USA
P14.11 Determination of the EGFR mutations including T790M in the cerebrospinal fluid of patients with leptomeningeal metastasis from EGFR mutant non small cell lung cancer
Authors: E. Le Rhun, V. Gregoire, E. Girard, I. Rodrigues, A. Baranzelli, C. Descarpentries, C. Maurage, A. Cortot, F. Escande
Journal: Neuro-Oncology (2017)
Quality Improvement and Accreditation
Authors: Rajesh Aggarwal
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
OS08.6 Fatigue in patients with surgically treated meningiomas
Authors: S. D. van der Linden, K. Gehring, G. J. M. Rutten, M. M. Sitskoorn
Journal: Neuro-Oncology (2017)

Introduction: Fatigue is a common symptom in patients with primary brain tumors and may have major impact on quality of life. However, little research has been done on fatigue in patients with a meningioma. The primary aim of this study was to examine the prevalence and severity of fatigue among patients with a meningioma one year after neurosurgery. Materials and Methods: This study is part of a larger ongoing study in brain tumor patients in the Elisabeth-TweeSteden Hospital Tilburg, The Netherlands. One year after surgery, patients with a meningioma (WHO grade I) completed the Multidimensional Fatigue Inventory (MFI). This 20-item self-report instrument covers five dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity. Patients’ scores were compared to representative normative data. Z-scores, corrected for age and sex, were calculated for each dimension. One-sample t-tests (test-value = 0) were conducted on the mean Z-scores, to evaluate patients’ level of fatigue at group level. By using cut-offs of Z-score > 1.65 and Z-score > 1.96, percentages of patients with (very) high fatigue scores were determined. Results: Twenty-eight meningioma patients (86% female), with a mean age of 55.8 (SD = 11.4) years, were included in the study. On average, patients scored significantly higher on all dimensions of the MFI (all p-values < .02). The largest mean differences in Z-scores were found on General Fatigue (Mdiff = 1.07) and Mental Fatigue (Mdiff = 1.03). Of 28 patients, 15 (54%) reported clinically relevant fatigue (Z-score > 1.65 on one or more dimensions of fatigue). Of these 15 patients, 13 scored even very high (Z-score > 1.96) on one or more dimensions of fatigue. Final results from a larger sample will be presented at the conference. Conclusion: This study systematically examines the prevalence and severity of fatigue in meningioma patients using a multidimensional instrument. Preliminary results demonstrate that, one year after surgery, clinically relevant fatigue is highly present in patients with a meningioma. This emphasizes the need for follow-up assessment and appropriate treatment for these patients.
HLA Ligandome Analysis of Primary Chronic Lymphocytic Leukemia (CLL) Cells Under In Vitro Lenalidomide Treatment Confirms Lenalidomide as a Suitable Combination Partner for T-Cell Based Immunotherapy
Authors: Annika Nelde, Daniel J. Kowalewski, Linus Backert, Heiko Schuster, Lothar Kanz, Helmut R. Salih, Hans-Georg Rammensee, Stefan Stevanovic, Juliane S. Stickel
Journal: Blood (2016)
P15.02 The accuracy of MRI for diagnosing intracranial lymphoma
Authors: H. J. Hopman, M. J. Wondergem, T. J. Postma
Journal: Neuro-Oncology (2017)

Introduction: Intracranial lymphoma is a rare but serious condition. Diagnostic workup includes at least a physical exam, cerebral spinal fluid examination and MRI, though the gold standard is stereotactic biopsy. Stereotactic biopsy is a procedure with possible complications, which include infection, bleeding and diagnostic delay. This inspired our ­multidisciplinary team to study the necessity of biopsy when a lesion is radiologically (very) suspicious for lymphoma. MRI features of lymphoma have been well-described. We investigated the accuracy of MRI for diagnosing intracranial lymphoma. Additionally, we aimed to explore diagnostic delay caused by the biopsy. Materials and methods: We conducted a retrospective single center database study, obtaining MRI reports and biopsy results of patients with brain lesions visiting our outpatient clinic in the past 5 years. We selected all patients with an MRI-report where lymphoma was mentioned as the only possible diagnosis or where lymphoma was mentioned in the differential diagnosis. Primary outcomes were sensitivity and positive predictive value (PPV) of MRI. Secondary outcomes were differences in sensitivity and PPV between subgroups and time between MRI, biopsy and treatment. Results: Positive MRIs had a sensitivity of 87.5%, 95% CI [64.0, 96.5] and PPV of 48.3%, 95% CI [31.4, 65.6]. All MRIs where lymphoma was the only possible diagnosis, had a biopsy proven lymphoma. Mean time in days between MRI and biopsy was 13.60 days, SD10.1, and between MRI and treatment 26.41 days, SD12.7. DISCUSSION: In this study, all MRIs that have lymphoma as their only possible diagnosis, had biopsy proven lymphoma. This suggests that these patients might not need a stereotactic biopsy to prove diagnosis. Further research is necessary to determine whether the same results come up in larger sample sizes and other study designs. In the meantime, our multidisciplinary team designed a diagnostic fast track for these patients, shortening the diagnostic delay caused by the need to biopsy.
Strengths, Risk Factors, and Resilient Outcomes in Adolescents With Type 1 Diabetes: Results From Diabetes MILES Youth–Australia
Authors: Marisa E. Hilliard, Virginia Hagger, Christel Hendrieckx, Barbara J. Anderson, Steven Trawley, Michelle M. Jack, Frans Pouwer, Timothy Skinner, Jane Speight
Journal: Diabetes Care (2017)

OBJECTIVE Despite the challenges of living with type 1 diabetes, many adolescents achieve “resilient outcomes”: high engagement in self-management behaviors such as self-monitoring of blood glucose (SMBG), good quality of life (QOL), and within-target glycemic outcomes (HbA1c). Adaptive diabetes-related behaviors (i.e., “strengths”) are associated with resilient outcomes, yet the combination of risks and strengths in relation to resilient outcomes is unclear. The aim of this study was to investigate relations among diabetes strengths and resilient outcomes in the context of psychological and family risk factors. RESEARCH DESIGN AND METHODS A total of 471 Australian adolescents with type 1 diabetes (mean age 15.7 ± 1.9 years; diabetes duration 6.9 ± 4.2 years; 62% female; 53% using insulin pumps) completed a national cross-sectional survey about their diabetes-related strengths, risk factors (depressive/anxiety symptoms, family conflict), and resilient outcomes (SMBG frequency, general QOL, HbA1c). RESULTS Greater diabetes strengths were significantly related to resilient outcomes: more frequent SMBG (r = 0.39), lower HbA1c (r = −0.31), and higher general QOL (r = 0.50), as well as to lower risks: fewer depressive (r = −0.45) and anxiety (r = −0.40) symptoms and less conflict (r = 0.28). In multivariate regressions, diabetes strengths consistently related to all resilient outcomes beyond significant risk factors. CONCLUSIONS In a large sample of Australian adolescents, diabetes strengths were strongly related to key resilient outcomes, even in the presence of well-documented psychological and family risk factors. More research is needed to determine whether strengths reduce or buffer other risks. Given the associations with self-management, HbA1c, and general QOL, monitoring and enhancing diabetes strengths may support resilience promotion during a vulnerable developmental period.
Labour pledges pay rise for NHS staff
Authors: Gareth Iacobucci
Journal: BMJ (2017)

The Labour Party has pledged to give NHS staff a pay rise if it wins the UK general election, as it seeks to put health at the forefront of its campaign.

The party will also legislate for minimum staffing levels in NHS trusts to prevent finances taking precedent over patient safety, and it plans to reinstate student bursaries for nurses and midwives if it wins the election on 8 June.

Unveiling the proposals in a speech at the Unison Health Conference in Liverpool on Wednesday 26 April, Labour’s shadow health secretary, Jonathan Ashworth, said that NHS staff had been “ignored, insulted, undervalued, overworked, and underpaid” by the Conservative government.

A Labour government would scrap the current government’s 1% cap on staff pay that …
Extramammary Paget’s Disease
Authors: Sarah H Mehrtens, Sriramulu Tharakaram
Journal: New England Journal of Medicine (2017)

An 89-year-old man presented with a 1-year history of a nonhealing groin rash that did not respond to antibiotics, antifungal agents, or glucocorticoids. A diagnosis of extramammary Paget’s disease was made by means of a skin biopsy.
Lung lymphoid neogenesis in cystic fibrosis: a model of adaptive responses to bacteria?
Authors: Sophie T. Gohy, Maha Z. Ladjemi, Charles Pilette
Journal: European Respiratory Journal (2017)

Cystic fibrosis and non-cystic fibrosis bronchiectasis share as their main clinical hallmark repeated lung infections by opportunist pathogens. In the normal adult lung, almost no lymphoid tissue is observed, in contrast to fetal and paediatric lungs [1] and in contrast to upper airways [2]. Neogenesis of bronchial-associated lymphoid tissue (BALT), also referred to as induced BALT (iBALT) or ectopic lymphoid follicles, has been observed in several chronic lung diseases, including chronic obstructive pulmonary disease (COPD) [3], lung cancer [4], pulmonary hypertension [5], post-transplant restrictive allograft syndrome [6] or rheumatoid lung [7], as well as possibly, to some extent, in asthma [8]. A distinction should thus be made between aggregates of B-cells without specific reorganisation and lymphoid follicle structures as observed in primary (bone marrow, thymus) and secondary lymphoid organs (lymph nodes, spleen and Peyer's patches). Lymphoid follicles contain mature naïve and memory B-cells, T-cells, dendritic cells and follicular dendritic cells organising in germinal centres and vascularised with lymphatics and high endothelial veinules. Such lymphoid follicles in non-lymphoid organs are called mucosal-associated lymphoid tissue in mucosal tissues and tertiary lymphoid follicles in other organs. Frija-Masson and co-workers draw definite conclusions on the role of pathogens for lymphoid neogenesis in the CF lung <http://ow.ly/v4iH309MbCs>
OS01.7 MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas
Authors: E. H. Bell, P. Zhang, K. Aldape, J. McElroy, M. Mehta, J. Fleming, Z. Liu, S. Coons, D. Johnson, A. Chakravarti
Journal: Neuro-Oncology (2017)

Background: This study sought to determine the proportion of patients with MGMT promoter methylation within NRG Oncology/RTOG 9802 and its prognostic significance in the setting of high-risk low-grade gliomas in a prospective phase III trial. Methods: NRG Oncology/RTOG 9802 enrolled 251 eligible high-risk patients, treated with RT or RT + PCV. The MGMT-STP27 prediction model was used to calculate MGMT promoter methylation status from Illumina HM-450K data. Univariate (UMAs) and multivariate analyses (MVAs) were performed using the Cox proportional hazard model, to analyze the effect of MGMT status on progression-free survival (PFS) and overall survival (OS). Patient pre-treatment characteristics and treatment assignment were included as covariates in MVAs. Results: Of all the eligible and randomized patients in this trial, 56 currently have MGMT status available: 43 (77%) methylated and 13 (23%) unmethylated. Between the two groups, no significant difference was observed on age and performance status at baseline. Majority of the unmethylated patients had astrocytoma dominant tumors as opposed to oligodendroglioma in the methylated group. Upon UVAs, MGMT promoter methylation was significantly correlated with better OS (HR = 2.66; p=0.01) and PFS (HR = 2.52; p=0.01). Upon MVAs, the statistical significance was maintained for PFS (HR = 3.57; p=0.001), but not OS (HR = 1.68; p=0.25). Conclusions:MGMT promoter methylation as determined by the MGMT- STP27 model was an independent prognostic biomarker of high-risk low-grade glioma treated with radiation or radiation plus PCV for PFS. Importantly, this is the first study to validate the prognostic significance of MGMT promoter methylation in a phase III study of high-risk grade II glioma patients treated with radiation plus/minus PCV using rigorous MVAs with prospectively-collected, well-annotated clinical data. Analysis of the prognostic significance of MGMT promoter methylation relative to IDH and 1p/19q status is ongoing as well as efforts to increase sample size. FUNDING: U10CA180868, U10CA180822, and U24CA196067 (NCI). Also, R01CA108633, R01CA169368, RC2CA148190, U10CA180850-01 (NCI), Brain Tumor Funders Collaborative Grant, and the Ohio State University CCC (all to AC).
P04.15 Diagnostic challenge of adult pilocytic astrocytoma with a thousand faces
Authors: H. Lee, J. Kim
Journal: Neuro-Oncology (2017)

Object: Pilocytic astrocytomas (PAs) are relatively rare in adults compared to children and have atypical radiological feature with various predilection sites such as suprasellar area, hypothalamus and brain stem. Despite the development of brain magnetic resonance imaging (MRI) techniques to acquire the advanced images, preoperative MRIs have often misinterpreted the PAs to be different tumors. The aim of this study was to reveal characteristic feature of adult PAs on radiologic studies that can discriminate them from other tumors. By reviewing adult patients with pathologically confirmed PAs, we analyzed the preoperative radiological diagnosis of PAs to reveal the characteristic findings that Methods: A total of 59 adult patients with newly diagnosed PAs were retrospectively reviewed. 31 patients (52.5%) were male, and the median patient age was 29 years (range, 18 - 79 years). All patient underwent surgeries either biopsy or resection of the tumor. There were 37 supratentorial tumors (62.7%), and 22 infratentorial tumors (37.3%). We analysed the frequency of the cases which were radiologically misinterpreted to be other type of tumors and compared those cases with the most frequently diagnosed tumors to reveal the characteristic radiologic feature of the PAs. Results: Among 59 patients, 13 patients (22%) were diagnosed with PAs on the preoperative MRIs. The most frequent preoperative radiological diagnosis for the infratentorial lesion was hemangioblastoma (8/59, 13.6%) followed by ependymoma (4/59, 6.8%). For the supratentorial lesion, low grade glioma (16.9%) was the most frequently diagnosed followed by ganglioglioma (4/59, 6.8%) and central neurocytoma (4/59, 6.8%). Comparing the PA cases with the counterpart groups such as hemagioblastoma and ganglioglioma, peritumoral edema was almost not present in PAs and enhancing portion of the lesion was larger comparing to the cyst diameter. The frequency of hydrocephalus was less common in infratentorial PA group than cerebellar hemagioblastoma. Conclusions: The adult PAs showed various radiological features and were often misdiagnosed to be other tumors on MRIs. Some radiologic characteristics seem to be specific for the diagnosis of the PAs.
Workload pressure would not be a defence against clinical negligence, barrister warns
Authors: Abi Rimmer
Journal: BMJ (2017)

Judges considering gross negligence manslaughter prosecutions against doctors would not view a lack of NHS resources as a defence against clinical negligence, a barrister who specialises in medical law and clinical negligence has said.

At a conference on litigation against doctors at the Royal Society of Medicine last week, James Badenoch QC said that he was often asked whether judges would take into account “the impossible conditions in which some doctors work.”

“The answer, to be relatively frank with you, is no,” he said. “We’ve often had discussions about whether financial …